Dr. Richardson on the Next Steps With CC-92480 Research in Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, discusses the next steps with the investigational cereblon E3 ligase modulator agent CC-92480 research in relapsed/refractory multiple myeloma.
Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center; institute physician, Dana-Farber Cancer Institute; and RJ Corman Professor of Medicine at Harvard Medical School, discusses the next steps with the investigational cereblon E3 ligase modulator agent CC-92480 research in relapsed/refractory multiple myeloma.
A phase 2 expansion cohort evaluating CC-92480 in combination with dexamethasone (Decadron) in patients with heavily pretreated relapsed/refractory multiple myeloma is ongoing, says Richardson.
Preclinical data suggest that CC-92480 is synergistic with other standard of care agents, such as monoclonal antibodies, proteasome inhibitors, and steroids, Richardson adds. Moreover, exciting a combination strategy with bortezomib (Velcade) and daratumumab (Darzalex) has demonstrated encouraging results thus far, Richardson explains.
The combination could lead to improved outcomes for patients with relapsed/refractory multiple myeloma, concludes Richardson.
